Complete Wegovy Dose Range: Start to Maintenance
Why Wegovy Dose Appears Lower Than Mounjaro: Understanding the Science
The question of why Wegovy's dose appears lower than Mounjaro reflects fundamental differences in their mechanisms rather than potency. Wegovy contains semaglutide, a GLP-1 receptor agonist that reaches its therapeutic ceiling at 2.4mg weekly, whilst Mounjaro contains tirzepatide, a dual GIP/GLP-1 agonist that escalates to 15mg weekly. These different milligram amounts cannot be directly compared as they represent entirely different molecules with distinct receptor binding profiles and pharmacokinetics.
At EverydayMeds, we maintain complete stock of all five Wegovy doses to support your entire treatment journey without pharmacy changes. Our comprehensive range includes 0.25mg starter doses through 2.4mg maintenance, with strategic bundles designed around the mandatory dose escalation schedule. Understanding why Wegovy's dose structure differs from Mounjaro helps patients appreciate that lower milligrams don't indicate reduced effectiveness - they simply reflect optimised dosing for semaglutide's specific mechanism of action.
Wegovy Pricing Structure: Complete Dose Range Investment
Our pricing reflects the complete Wegovy dose escalation journey, starting with 0.25mg pens at £79.99 (with FIRST40 discount code applied at checkout) progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99) to maintenance 2.4mg at £209.99. New customers benefit from the FIRST40 discount code, whilst returning patients use DOSE25, both applied at checkout to reach these final prices. The gradual price increase mirrors the enhanced potency and manufacturing complexity of higher doses.
Understanding why Wegovy's dose progression differs from Mounjaro's helps explain our bundle strategy, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, providing your first two months of treatment in one convenient order. Our Ultimate Stability Trio offers three months of 2.4mg maintenance supply for £649.99, ensuring consistent access once you've reached therapeutic dosing. These bundles eliminate supply uncertainty while maintaining the precise escalation schedule required for this prescription-only medicine.
Clinical Evidence: Why Lower Doses Deliver Results
The STEP clinical trial programme demonstrates why Wegovy's seemingly lower doses compared to Mounjaro achieve significant outcomes. In STEP 1, published by Wilding et al. in NEJM 2021, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks versus 2.4% with placebo. The STEP 5 trial confirmed sustained weight management of approximately 15.2% at two years, validating the 2.4mg maintenance dose effectiveness.
These results explain why Wegovy's dose appears lower than Mounjaro - semaglutide's selective GLP-1 receptor targeting achieves therapeutic goals without requiring the higher milligram amounts needed for dual receptor agonism. The SELECT cardiovascular outcomes trial further demonstrated a 20% reduction in major cardiovascular events, reinforcing that Wegovy's dose optimization prioritizes both efficacy and safety profiles for long-term treatment.
How Wegovy's Mechanism Explains Lower Dosing Requirements
Wegovy functions as a GLP-1 receptor agonist, mimicking your body's natural incretin hormone that signals satiety after meals and regulates glucose-dependent insulin release. This targeted approach explains why Wegovy's dose appears lower than Mounjaro's dual-receptor strategy - semaglutide achieves appetite suppression and delayed gastric emptying through focused GLP-1 pathway activation. The medication works on brain appetite centres to reduce food cravings whilst promoting feelings of fullness after smaller meals. Understanding this mechanism clarifies why 2.4mg represents the therapeutic ceiling for semaglutide, as higher doses don't proportionally increase GLP-1 receptor activation. This precision targeting eliminates the need for higher milligram amounts required by multi-pathway approaches.
Streamlined Ordering Process Across All Wegovy Doses
Our three-minute online clinical assessment covers your complete treatment journey, from understanding why Wegovy's dose progression differs from Mounjaro through to maintenance planning. Qualified prescribers review your assessment within standard three working days (or 24 hours with express service), evaluating your suitability for each escalation phase. Once approved, we dispatch your Wegovy via next-day delivery using cold-chain temperature-controlled packaging, maintaining the 2-8°C storage requirements until it reaches your door. Our GPhC-registered pharmacy status (#9012878) ensures full regulatory compliance for this prescription-only medicine. The entire process accommodates both single pen orders and multi-dose bundles, supporting flexible treatment planning throughout your dose escalation schedule.
Storage Advantages: Why Wegovy Dose Flexibility Matters
Understanding why Wegovy's dose appears lower than Mounjaro extends to practical considerations like storage flexibility, where Wegovy offers superior convenience. Once removed from refrigeration, Wegovy pens remain stable for six weeks at room temperature below 30°C, compared to Mounjaro's 21-day limit. This storage advantage becomes particularly relevant during dose escalation, when patients may be managing multiple pen strengths or travelling between doses. The FlexTouch pen delivery system maintains dose accuracy across all five strengths, from 0.25mg through 2.4mg, ensuring consistent medication delivery regardless of which escalation phase you're experiencing. Proper storage supports the mandatory dose escalation schedule that distinguishes Wegovy's approach from other weight management strategies.
Complete Dose Journey Support: Beyond Initial Comparisons
While understanding why Wegovy's dose appears lower than Mounjaro addresses immediate comparison questions, successful treatment requires comprehensive support throughout the entire escalation journey. Our pharmacy maintains deep stock levels across all five dose strengths, eliminating supply chain disruptions that could compromise your treatment continuity. The mandatory four-week intervals between dose increases mean patients require reliable access to each subsequent strength, making pharmacy consistency crucial for optimal outcomes.
This complete dose availability distinguishes our service from suppliers focusing only on popular strengths, ensuring you never face treatment interruption due to stock limitations. Our bundles like the Progress Trio (0.5mg, 1mg & 1.7mg) for £369.99 provide strategic dose combinations that align with escalation timelines, demonstrating why choosing a pharmacy with comprehensive range matters more than initial price comparisons alone.
Expert Clinical Support and Next Steps
Understanding why Wegovy's dose appears lower than Mounjaro represents just the beginning of your weight management journey with this prescription-only medicine. Both Wegovy and Mounjaro are available from EverydayMeds - your prescriber can help determine which approach aligns with your individual circumstances, medical history, and treatment goals. Our clinical team supports patients throughout the entire dose escalation process, from initial 0.25mg starter doses through 2.4mg maintenance, ensuring optimal tolerance and effectiveness. Use discount code FIRST40 for new customers or DOSE25 for returning patients at checkout, then begin your assessment at our Wegovy collection. Start your comprehensive treatment journey with the UK's most complete dose range, supported by GPhC-registered expertise and nationwide next-day delivery.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
